AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3039130
Drug: Unprocessed bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprocessed bran 5 g three times daily
Trial: 3039130
Drug: Unprocessed bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprocessed bran 2.5 g three times daily
Trial: 16532872
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional treatment)
Trial: 28578607
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus prednisone (1000 mg daily, given once daily as four 250-mg tablets; prednisone 5 mg daily)
Trial: 11932859
Drug: Flexible frozen
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible frozen gel pack
Trial: 9800740
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg per day)
Trial: 2548551
Drug: Cilazapril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (4 mg)
Trial: 132566
Drug: Ipratropiumbromide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropiumbromide (30 mg or more)
Trial: 29699723
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine racemate
Trial: 20156055
Drug: Arm I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm I: Isoniazid, rifampicin, and pyrazinamide simultaneously at full dosage from day 1
Trial: 20156055
Drug: Arm II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm II: Drugs administered according to American Thoracic Society guidelines
Trial: 20156055
Drug: Arm III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm III: Drugs administered according to British Thoracic Society guidelines
Trial: 18030209
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (0.25 mg/kg subcutaneously each week)
Trial: 7884421
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (cyclophosphamide 7.2 g/m2, carmustine 300 mg/m2 or 600 mg/m2, etoposide 2,400 mg/m2) followed by allogeneic bone marrow transplantation (allo BMT)
Trial: 7884421
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (carmustine 600 mg/m2)
Trial: 7884421
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (carmustine 300 mg/m2)
Trial: 7884421
Drug: Allo BMT
RxNorm normalized name: allo-2-hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allo BMT following high-dose CBV regimen
Trial: 638577
Drug: Aminophylline 1
RxNorm normalized name: aminophylline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 1 mg/min
Trial: 31744484
Drug: Peer evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer evaluation in pharmacodynamics items (PE-PD)
Trial: 31744484
Drug: Peer evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer evaluation in pharmacokinetics items (PE-PK)
Trial: 31744484
Drug: Teachers' marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teachers' marks for oral presentation (PE-PD)
Trial: 31744484
Drug: Teachers' marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teachers' marks for oral presentation (PE-PK)
Trial: 20146877
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice a day (bid)
Trial: 20146877
Drug: Tramadol HCl
RxNorm normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol HCl 50 mg four times a day (qid)
Trial: 16321614
Drug: Bradykinin B(2)
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin B(2) receptor antagonist HOE 140 (100 mug/kg)
Trial: 12029261
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III (ATIII) administration
Trial: 12029261
Drug: Heparin (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (concomitant use)
Trial: 30421441
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bolus of cangrelor (30 μg/kg) followed by a 120‐minute infusion (4 μg/kg/min)
Trial: 23125443
Drug: Ad26.ENVA.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ENVA.01 vaccine
Trial: 10482146
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ticlopidine
Trial: 11358941
Drug: Adrenomedullin high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin high dose (5.8 pmol/kg per minute)
Trial: 11358941
Drug: Adrenomedullin low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin low dose (2.9 pmol/kg per minute)
Trial: 9433365
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of 10 mg cetirizine daily
Trial: 9433365
Drug: On demand
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On demand treatment with cetirizine
Trial: 8357678
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin E2 (PGE2) gel at a dose of 0.3 mg twice daily for 10 days
Trial: 3693870
Drug: Individualized dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dose of amitriptyline calculated by a pharmacokinetic test
Trial: 3693870
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of amitriptyline
Trial: 3693870
Drug: Individualized dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dose of amitriptyline
Trial: 28966061
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (suture anchor technique)
Trial: 19545929
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/m² on day 1 and pemetrexed 500 mg/m² followed by gemcitabine 1250 mg/m² on day 8 of a 3-week cycle (GA arm)
Trial: 19545929
Drug: Paclitaxel 120
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 120 mg/m² followed by gemcitabine 1000 mg/m² on days 1 and 8 of a 3-week cycle (PG arm)
Trial: 18974515
Drug: Two hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hours occlusion therapy
Trial: 18974515
Drug: Four hours
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hours occlusion therapy
Trial: 18974515
Drug: Six hours
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six hours occlusion therapy
Trial: 18974515
Drug: Full-time occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-time occlusion therapy
Trial: 16828460
Drug: 1-day behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day behavioral group treatment (BGT) program
Trial: 16828460
Drug: 2-day cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day cognitive-behavioral group treatment (CBGT) program
Trial: 1360452
Drug: Combination FSH/hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination FSH/hMG
Trial: 29666901
Drug: Subcutaneous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dexmedetomidine (1 μg/kg)
Trial: 29666901
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (1 μg/kg)
Trial: 25531119
Drug: 3.0 mEq/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mEq/l dialysate calcium
Trial: 25531119
Drug: 2.5 mEq/l
RxNorm normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mEq/l dialysate calcium
Trial: 12725416
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate 2 mg/dienogest 2 mg (E2V/DNG)
Trial: 12725416
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Trial: 1655056
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g in a single dose
Trial: 1655056
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg in a single dose on day 1 followed by 250 mg once daily for 2 days
Trial: 1655056
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg in a loading dose followed by 100 mg every 12 h for 7 days
Trial: 6820887
Drug: Futraful (more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futraful (more than 60 g)
Trial: 6820887
Drug: Method II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method II (large dose MMC) plus Futraful
Trial: 29532291
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg kg-1
Trial: 29532291
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) 6 mg kg-1 of maltodextrin
Trial: 28130432
Drug: Azithromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (2 g)
Trial: 25811544
Drug: L-glutamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (0.3 g·kg‐1·day‐1 + 0.3 g·kg‐1·day‐1 maltodextrin)
Trial: 10956377
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine
Trial: 25811544
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 0.6 g·kg‐1·day‐1)
Trial: 24092942
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering regimens (various drug classes including ACE inhibitors, calcium antagonists, diuretics/β blockers)
Trial: 19153290
Drug: Crosseal (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crosseal (2 mL sprayed under the skin flap)
Trial: 16199249
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg/d for 10 days
Trial: 10193720
Drug: Paroxetine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine at 20 mg once a day
Trial: 8520811
Drug: MID 10
RxNorm normalized name: Revlimid 10mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID 10 mg + 150 mg fluconazole (FLU)
Trial: 8520811
Drug: MID 10
RxNorm normalized name: Revlimid 10mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID 10 mg
Trial: 8520811
Drug: MID 10
RxNorm normalized name: Revlimid 10mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID 10 mg after FLU
Trial: 8520811
Drug: MID 10
RxNorm normalized name: Revlimid 10mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID 10 mg after 750 mg erythromycin (ERY)
Trial: 8520811
Drug: MID 10
RxNorm normalized name: Revlimid 10mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID 10 mg alone
Trial: 2271746
Drug: Midaglizole 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 150 mg
Trial: 2271746
Drug: Midaglizole 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 200 mg
Trial: 2271746
Drug: Midaglizole 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 300 mg
Trial: 2271746
Drug: Midaglizole 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 500 mg
Trial: 2271746
Drug: Midaglizole 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 200 mg (30 min after breakfast)
Trial: 2271746
Drug: Midaglizole 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole 200 mg t.i.d. (20 min before meals for 7 days)
Trial: 2271746
Drug: Midaglizole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole (all doses)
Trial: 7416592
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 50 mg of naloxone
Trial: 7416592
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion of normal saline
Trial: 31831920
Drug: Mupirocin 2%
RxNorm normalized name: MUPIROCIN 2% OINT
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin 2% and Sucralfate 7% combination
Trial: 27379961
Drug: Midcooling (facial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midcooling (facial water spray and menthol mouth rinse)
Trial: 19265095
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic drugs (flecainide, propafenone)
Trial: 19265095
Drug: Class III
RxNorm normalized name: HLA class III antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class III antiarrhythmic drug (amiodarone)
Trial: 19265095
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers and rate limiting calcium blockers, digoxin
Trial: 11522497
Drug: epalrestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epalrestat (150 mg/day) for 5 years
Trial: 9640123
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion of Propofol
Trial: 9640123
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled Infusion of Propofol
Trial: 26188896
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of procaine 0.5% at 4-5 ml/h for 48 hours via elastomeric pump
Trial: 26188896
Drug: Standard post-operative
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-operative pain regimen of metamizole 1 g and/or ketorolac 3% - 30 mg
Trial: 17237328
Drug: Combined iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined iron (10 mg) and zinc (10 mg) supplementation for 6 months
Trial: 17237328
Drug: Iron (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (10 mg) supplementation for 6 months
Trial: 17237328
Drug: Zinc (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (10 mg) supplementation for 6 months
Trial: 17237328
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A capsules (VAC) administration
Trial: 7786974
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy combined with anti-depressive medication
Trial: 7786974
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only anti-depressive medication
Trial: 1972349
Drug: Xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 200 mg twice daily for 3 months
Trial: 119258
Drug: +amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +amphetamine (10 mg)
Trial: 119258
Drug: +/-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +/-fenfluramine (30 mg and 60 mg)
Trial: 25731132
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention targeting cognitive dysfunction, including education on cognitive function, self-awareness training, compensatory strategies, and problem-solving therapy; formal working memory training in a subgroup.
Trial: 24083804
Drug: eplerenone (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone (target dose 50mg)
Trial: 9833847
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg abacavir twice daily
Trial: 9833847
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg abacavir twice daily
Trial: 9833847
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg abacavir twice daily
Trial: 9833847
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg abacavir + zidovudine + lamivudine (open-label phase)
Trial: 8135426
Drug: IV phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV phenytoin (15 mg/kg over 20 minutes)
Trial: 28027625
Drug: Calcineurin Inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin Inhibitor (CNI) (n = 356)
Trial: 19957560
Drug: Betaferon with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaferon with a reduced dosage regimen (2 MIU, 4 MIU, and 8 MIU) subcutaneously, varying by week (Group B)
Trial: 16366421
Drug: HCA-SX 4,667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCA-SX 4,667 mg (providing 2,800 mg HCA per day)
Trial: 16366421
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HCA-SX 4,667 mg, niacin-bound chromium (NBC) 4 mg, and Gymnema sylvestre extract (GSE) 400 mg
Trial: 7624991
Drug: Goserelin, 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin, 3.6 mg every 28 days
Trial: 16023214
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for high-risk prethreshold ROP (n = 317 eyes)
Trial: 16023214
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management when regression without treatment occurred
Trial: 16023214
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment at high-risk prethreshold ROP with abnormal angle of temporal retinal vessels or macular ectopia
Trial: 16023214
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment at high-risk prethreshold ROP with no retinal residua
Trial: 11920310
Drug: high-dose IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose IFN
Trial: 10334540
Drug: CDDP 50
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 50 mg/m2, GEM 1,000 mg/m2, and VNR 25 mg/m2 on days 1 and 8 of an every-3-weeks cycle (arm A)
Trial: 10334540
Drug: CDDP 80
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 80 mg/m2, epirubicin 80 mg/m2, and vindesine 3 mg/m2 on day 1 every 4 weeks, plus lonidamine orally 150 mg three times daily (arm B)
Trial: 10334540
Drug: CDDP-GEM-VNR combination
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP-GEM-VNR combination (arm A)
Trial: 10334540
Drug: CDDP-epirubicin-vindesine-lonidamine combination
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP-epirubicin-vindesine-lonidamine combination (arm B)
Trial: 1669483
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml (0.5%) timolol maleate
Trial: 1669483
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (comparison group)
Trial: 31529194
Drug: Prevena™ negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevena™ negative pressure wound therapy
Trial: 31529194
Drug: PICO™ negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PICO™ negative pressure wound therapy
Trial: 9491788
Drug: oxaliplatin (L-OHP®)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin (L-OHP®) in combination with continuous infusion 5-FU
Trial: 7857999
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of weekly sessions of supervised group physical therapy
Trial: 7857999
Drug: Unsupervised daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised daily exercises at home (discontinuation group)
Trial: 2892520
Drug: Temazepam elixir
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temazepam elixir 30 mg by mouth
Trial: 2892520
Drug: Diazemuls i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazemuls i.v. titrated to a maximum dose of 20 mg
Trial: 26187303
Drug: Mobile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobile Insulin Titration Intervention (MITI) using SMS text messages and phone calls